

Kye Young Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9425374/publications.pdf>

Version: 2024-02-01

23
papers

3,685
citations

623574

14
h-index

642610

23
g-index

23
all docs

23
docs citations

23
times ranked

4523
citing authors

#	ARTICLE	IF	CITATIONS
1	Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2286-2296.	3.2	14
2	Extracellular Vesicle-Based Bronchoalveolar Lavage Fluid Liquid Biopsy for EGFR Mutation Testing in Advanced Non-Squamous NSCLC. <i>Cancers</i> , 2022, 14, 2744.	1.7	9
3	Targeted Next-Generation Sequencing Analysis for Recurrence in Early-Stage Lung Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 3983-3993.	0.7	26
4	ASO Author Reflections: CTNNB1 and Fusion Genes as Predictors for Recurrence in Resected Early-Stage Lung Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 3994-3995.	0.7	2
5	Genomic profiling of extracellular vesicle-derived DNA from bronchoalveolar lavage fluid of patients with lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 104-116.	1.3	13
6	Targeted Next-Generation Sequencing Analysis Predicts the Recurrence in Resected Lung Adenocarcinoma Harboring EGFR Mutations. <i>Cancers</i> , 2021, 13, 3632.	1.7	3
7	Characteristics and Clinical Application of Extracellular Vesicle-Derived DNA. <i>Cancers</i> , 2021, 13, 3827.	1.7	22
8	Liquid biopsy using extracellular vesicle-derived DNA in lung adenocarcinoma. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 453-461.	0.4	16
9	Extracellular vesicle-based EGFR genotyping in bronchoalveolar lavage fluid from treatment-naïve non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2019, 8, 1051-1060.	1.3	35
10	Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA. <i>BMC Cancer</i> , 2018, 18, 1236.	1.1	65
11	Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study. <i>BMC Cancer</i> , 2018, 18, 768.	1.1	18
12	Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients. <i>Molecular Cancer</i> , 2018, 17, 15.	7.9	57
13	Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non-Small-cell Lung Cancer: A TRAIL Trial. <i>Clinical Lung Cancer</i> , 2017, 18, e289-e296.	1.1	21
14	A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non-Small Cell Lung Cancer Patient. <i>Journal of Thoracic Oncology</i> , 2017, 12, e179-e181.	0.5	3
15	Detection of EGFR and KRAS Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer. <i>Journal of Korean Medical Science</i> , 2016, 31, 1224.	1.1	9
16	Clinical features of lung adenocarcinomas with epidermal growth factor receptor mutations and miliary disseminated carcinomatosis. <i>Thoracic Cancer</i> , 2015, 6, 629-635.	0.8	12
17	The Korean guideline for lung cancer screening. <i>Journal of the Korean Medical Association</i> , 2015, 58, 291.	0.1	32
18	The performance of a novel amino acid multivariate index for detecting lung cancer: A case control study in Korea. <i>Lung Cancer</i> , 2015, 90, 522-527.	0.9	43

#	ARTICLE	IF	CITATIONS
19	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2015, 16, 141-151.	5.1	1,369
20	FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 89-98.	1.2	88
21	Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment. <i>Lung Cancer</i> , 2014, 83, 252-258.	0.9	18
22	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 213-222.	5.1	1,740
23	Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2012, 75, 321-325.	0.9	70